G1 Therapeutics Probability of Future Stock Price Finishing Under 7.15

GTHXDelisted Stock  USD 7.15  0.00  0.00%   
G1 Therapeutics' future price is the expected price of G1 Therapeutics instrument. It is based on its current growth rate as well as the projected cash flow expected by the investors. This tool provides a mechanism to make assumptions about the upside potential and downside risk of G1 Therapeutics performance during a given time horizon utilizing its historical volatility. Check out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in rate.
  
Please specify G1 Therapeutics' target price for which you would like G1 Therapeutics odds to be computed.

G1 Therapeutics Target Price Odds to finish below 7.15

The tendency of GTHX Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
Current PriceHorizonTarget PriceOdds to move below current price in 90 days
 7.15 90 days 7.15 
about 86.44
Based on a normal probability distribution, the odds of G1 Therapeutics to move below current price in 90 days from now is about 86.44 (This G1 Therapeutics probability density function shows the probability of GTHX Stock to fall within a particular range of prices over 90 days) .
Given the investment horizon of 90 days G1 Therapeutics has a beta of -0.5. This usually indicates as returns on the benchmark increase, returns on holding G1 Therapeutics are expected to decrease at a much lower rate. During a bear market, however, G1 Therapeutics is likely to outperform the market. Moreover G1 Therapeutics has an alpha of 1.615, implying that it can generate a 1.61 percent excess return over Dow Jones Industrial after adjusting for the inherited market risk (beta).
   G1 Therapeutics Price Density   
       Price  

Predictive Modules for G1 Therapeutics

There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as G1 Therapeutics. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.
Hype
Prediction
LowEstimatedHigh
7.157.157.15
Details
Intrinsic
Valuation
LowRealHigh
5.035.037.87
Details
Please note, it is not enough to conduct a financial or market analysis of a single entity such as G1 Therapeutics. Your research has to be compared to or analyzed against G1 Therapeutics' peers to derive any actionable benefits. When done correctly, G1 Therapeutics' competitive analysis will give you plenty of quantitative and qualitative data to validate your investment decisions or develop an entirely new strategy toward taking a position in G1 Therapeutics.

G1 Therapeutics Risk Indicators

For the most part, the last 10-20 years have been a very volatile time for the stock market. G1 Therapeutics is not an exception. The market had few large corrections towards the G1 Therapeutics' value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold G1 Therapeutics, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of G1 Therapeutics within the framework of very fundamental risk indicators.
α
Alpha over Dow Jones
1.61
β
Beta against Dow Jones-0.5
σ
Overall volatility
2.05
Ir
Information ratio 0.18

G1 Therapeutics Alerts and Suggestions

In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of G1 Therapeutics for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for G1 Therapeutics can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.
G1 Therapeutics is not yet fully synchronised with the market data
G1 Therapeutics has a very high chance of going through financial distress in the upcoming years
The company reported the previous year's revenue of 82.51 M. Net Loss for the year was (47.97 M) with profit before overhead, payroll, taxes, and interest of 47.55 M.
G1 Therapeutics currently holds about 143.96 M in cash with (38.34 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 3.37.

G1 Therapeutics Price Density Drivers

Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of GTHX Stock often depends not only on the future outlook of the current and potential G1 Therapeutics' investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. G1 Therapeutics' indicators that are reflective of the short sentiment are summarized in the table below.
Common Stock Shares Outstanding51.7 M
Cash And Short Term Investments82.2 M

G1 Therapeutics Technical Analysis

G1 Therapeutics' future price can be derived by breaking down and analyzing its technical indicators over time. GTHX Stock technical analysis helps investors analyze different prices and returns patterns as well as diagnose historical swings to determine the real value of G1 Therapeutics. In general, you should focus on analyzing GTHX Stock price patterns and their correlations with different microeconomic environments and drivers.

G1 Therapeutics Predictive Forecast Models

G1 Therapeutics' time-series forecasting models is one of many G1 Therapeutics' stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models are widely used for non-stationary data. Non-stationary data are called the data whose statistical properties, e.g., the mean and standard deviation, are not constant over time, but instead, these metrics vary over time. This non-stationary G1 Therapeutics' historical data is usually called time series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the stock market movement and maximize returns from investment trading.

Things to note about G1 Therapeutics

Checking the ongoing alerts about G1 Therapeutics for important developments is a great way to find new opportunities for your next move. Our stock alerts and notifications screener for G1 Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.
G1 Therapeutics is not yet fully synchronised with the market data
G1 Therapeutics has a very high chance of going through financial distress in the upcoming years
The company reported the previous year's revenue of 82.51 M. Net Loss for the year was (47.97 M) with profit before overhead, payroll, taxes, and interest of 47.55 M.
G1 Therapeutics currently holds about 143.96 M in cash with (38.34 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 3.37.
Check out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in rate.
You can also try the Risk-Return Analysis module to view associations between returns expected from investment and the risk you assume.

Other Consideration for investing in GTHX Stock

If you are still planning to invest in G1 Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the G1 Therapeutics' history and understand the potential risks before investing.
Sync Your Broker
Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors.
Balance Of Power
Check stock momentum by analyzing Balance Of Power indicator and other technical ratios
Premium Stories
Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope
Top Crypto Exchanges
Search and analyze digital assets across top global cryptocurrency exchanges
Bollinger Bands
Use Bollinger Bands indicator to analyze target price for a given investing horizon
CEOs Directory
Screen CEOs from public companies around the world
Money Flow Index
Determine momentum by analyzing Money Flow Index and other technical indicators
FinTech Suite
Use AI to screen and filter profitable investment opportunities
Sign In To Macroaxis
Sign in to explore Macroaxis' wealth optimization platform and fintech modules